# EXXUA - (18.2MG, 36.3MG, 54.5MG, 72.6MG ; TABLET,EXTENDED RELEASE)

| | | | |
|---|---|---|---|
| **Generic Name** | GEPIRONE HYDROCHLORIDE | **Innovator** | FABRE KRAMER |
| **Dosage** | 18.2MG, 36.3MG, 54.5MG, 72.6MG ; TABLET,EXTENDED RELEASE | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | None | **Known Para IV Filers** | None |
| **Other ANDA developers** | None | **Tentative Approvals** | None |
| **Final Approvals** | None | **Generic Launches** | None |
| **Indication** | EXXUA is indicated for the treatment of major depressive disorder (MDD) in adults. | | |
| **Complexities** | Yes | | |

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.